Company Profile
Early detection of cancer dramatically enhances a patient’s chances of survival. Currently there is a large unmet medical need for early detection, as well as a need for tests that are simpler and less invasive. Pacific Edge Biotechnology specializes in the development and commercialization of diagnostics and prognostics for cancer.
Pacific Edge Biotechnology’s business is the discovery, development and commercialization of new, simple to use genomic and proteomic technology for the earlier detection, improved characterization and better management of gastric, bladder, endometrial, colorectal cancers and melanoma.
The company’s latest product allows for the early detection and monitoring of bladder cancer. This new assay has currently in clinical trial and is expected to be completed in late 2008.
